Percheron Therapeutics Limited has released a press release.
ATL1102 DMD Paediatric Investigation Plan submitted to EMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Half Yearly Report and Half Year Accounts
- ANP meeting with US FDA granted for ATL1102 in DMD
- Quarterly Update and Appendix 4C
- Annual General Meeting Chairmans Address
- EC grants Orphan Drug Designation for ATL1102 in DMD
Later from Percheron Therapeutics
- US FDA Type C Meeting for ATL1102 in DMD
- Manufacture of ATL1102 clinical supplies for Phase IIb trial
- US FDA Feedback on Type C Meeting for ATL1102 in the US
- ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
- ANP and MCRI new R&D collaboration for ATL1102
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics